Table 2.
Death and Major Adverse Cardiac Event (MACE) by group and viral variant
| CVD (-) | CVD ( +) | Cardioonc (-) | Cardioonc ( +) | Total | p-value* | ||
|---|---|---|---|---|---|---|---|
| Early SARS-CoV-2 | Total cases | 217,282 | 22,137 | 50,212 | 737 | 290,368 | |
| Death (%) | 11.1 | 22.8 | 26.2 | 37.6 | 14.6 | < 0.001 | |
| MACE (%) | 43.1 | 46.5 | 47.3 | 54.5 | 44.1 | < 0.001 | |
| Alpha | Total cases | 51,579 | 9923 | 8870 | 324 | 70,696 | |
| Death (%) | 6.9 | 19.0 | 17.3 | 30.9 | 10.0 | < 0.001 | |
| MACE (%) | 38.1 | 41.8 | 37.1 | 49.4 | 38.6 | < 0.001 | |
| Delta | Total cases | 34,064 | 6440 | 5682 | 262 | 70,696 | |
| Death (%) | 5.5 | 16.7 | 13.8 | 22.5 | 8.2 | < 0.001 | |
| MACE (%) | 36.2 | 37.0 | 33.0 | 40.8 | 36.0 | < 0.001 | |
| Omicron | Total cases | 6161 | 2166 | 1057 | 68 | 9452 | |
| Death (%) | 3.7 | 14.0 | 8.9 | 20.6 | 6.8 | < 0.001 | |
| MACE (%) | 33.8 | 34.9 | 25.5 | 35.3 | 33.2 | < 0.001 |
CVD (-) Cardiovascular Disease and SARS-CoV-2 negative, Cardioonc (-) Cardiovascular Disease and Active Cancer and SARS-CoV-2 negative, Cardioonc ( +) Cardiovascular Disease and Active Cancer and SARS-CoV-2 positive, CVD ( +) Cardiovascular Disease and SARS-CoV-2 positive
*Chi-square test with p-values was used to assess the proportions among four different cohorts